Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019–2023)

20250 citationsJournal Articlediamond Open Access

Authors

The findings of this study suggest that apalutamide may result in better economic outcomes relative to enzalutamide.

Zero hunger

Published in: Journal of Medical Economics

Volume 28, Issue 1, pp. 1096-1109

Field-Weighted Citation Impact: 0.00